MedTrace Logo

Single-dose Crossover Study to Investigate Pharmacodynamics of AZD3199

NCT00736489 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2014-05-19

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to investigate the pharmacodynamics of single doses of AZD3199 in asthmatic patients.

Conditions

Interventions

DRUG

AZD3199

Dry powder for inhalation, single dose

DRUG

Formoterol

Dry powder for inhalation, single dose

DRUG

Placebo

Dry powder for inhalation, single dose

Sponsors & Collaborators

Principal Investigators

  • Prof Leif Bjermer, MD, PhD · University Hospital in Lund, Sweden

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2008-12-31
Completion
2008-12-31

Countries

  • Denmark
  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00736489 on ClinicalTrials.gov